We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · October 02, 2019

ESMO 2019: KATE2 Suggests Benefit of Atezolizumab in PD-L1-Positive, HER2-Positive Breast Cancer

Study authors recommend further study of HER2-targeted agents plus atezolizumab in this patient population

PracticeUpdate Editorial Team

 

Further Reading